Good morning :)
Place Order
Add to Watchlist

Kwality Pharmaceuticals Ltd

KPL

Kwality Pharmaceuticals Ltd

KPL
Health CarePharmaceuticals
SmallcapWith a market cap of ₹843 cr, stock is ranked 1,563
High RiskStock is 3.47x as volatile as Nifty
812.952.28% (+18.15)
812.952.28% (+18.15)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹843 cr, stock is ranked 1,563
High RiskStock is 3.47x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹843 cr, stock is ranked 1,563
High RiskStock is 3.47x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
31.663.79
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
52.566.720.47%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Kwality Pharmaceuticals Limited manufactures and exports pharmaceutical formulations for human and veterinary use.

Investor Presentation

View older 

May 27, 2024

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 13.11%, vs industry avg of 9.03%

Constant Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share stayed at 0.08%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 25.74%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue74.5399.53138.29166.90142.96263.60459.70253.97309.00321.51
Raw Materialssubtract57.4872.19104.00114.1992.59165.50203.11113.27154.66257.02
Power & Fuel Costsubtract2.312.812.763.714.206.1311.0712.9817.23
Employee Costsubtract2.163.604.897.7410.9214.7018.8028.1630.46
Selling & Administrative Expensessubtract5.358.9111.0713.7119.5941.7048.7432.6430.91
Operating & Other expensessubtract1.851.913.1011.22-2.225.122.8019.7914.70
Depreciation/Amortizationsubtract1.692.512.983.124.436.4910.6914.9619.5618.80
Interest & Other Itemssubtract1.221.952.212.292.522.682.926.6110.3910.68
Taxes & Other Itemssubtract0.922.282.753.352.606.1241.576.217.308.37
EPS0.772.224.377.308.0314.61115.6518.6522.9325.67
DPS0.000.300.000.000.000.000.000.000.00
Payout ratio0.000.140.000.000.000.000.000.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2024

Annual report

PDF

Investor Presentation

May 27PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Kwality Pharmaceuticals Ltd35.453.79
Sun Pharmaceutical Industries Ltd47.576.790.71%
Cipla Ltd30.804.740.83%
Torrent Pharmaceuticals Ltd71.4717.270.80%

Price Comparison

Compare KPL with any stock or ETF
Compare KPL with any stock or ETF
KPL
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding54.83%0.00%0.00%0.00%45.17%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

MarJunSepDec '23MarJun0.00%0.00%0.00%0.00%0.00%0.00%

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

KPL has not given any dividends in last 5 years

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJan 5, 2017

Interim
Interim | Div/Share: ₹0.60

Dividend/Share

0.60

Ex DateEx Date

Jan 5, 2017

News & Opinions
Corporate
Kwality Pharmaceuticals schedules AGM

Kwality Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Kwality Pharmaceuticals to conduct AGM

Kwality Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Kwality Pharmaceuticals consolidated net profit rises 54.24% in the June 2024 quarter

Net profit of Kwality Pharmaceuticals rose 54.24% to Rs 8.36 crore in the quarter ended June 2024 as against Rs 5.42 crore during the previous quarter ended June 2023. Sales rose 18.72% to Rs 80.08 crore in the quarter ended June 2024 as against Rs 67.45 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales80.0867.45 19 OPM %21.6520.42 - PBDT15.1411.98 26 PBT11.127.20 54 NP8.365.42 54 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Kwality Pharmaceuticals to discuss results

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live